Corporate Banner
Satellite Banner
Biomolecular Screening
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

European Lead Factory - A Major New Drug Discovery Initiative

Published: Monday, January 27, 2014
Last Updated: Monday, January 27, 2014
Bookmark and Share
The European Lead Factory is the first of its kind and will provide a novel platform for innovative drug discovery.

Titian Software announces that its Mosaic software is to play a central role in compound library screening for a major new European drug discovery initiative, the European Lead Factory (ELF).  Following a successful bid to the Innovative Medicines Initiative (IMI), over 8.7m euros has been invested by BioCity Scotland (BCS) to establish a compound management facility at Newhouse Scotland, and selected Titian’s Mosaic sample management software for streamlining compound operations.   

BioCity Scotland has created a life sciences hub at Newhouse Scotland in the former Organon/Shering Plough/MSD site close to the busy M8 corridor, which offers highly equipped chemistry laboratories to small and medium sized businesses along with offices and other business premises for hire.  A major part of this centre is the revived compound management centre, in which the Mosaic software had previously been deployed. 

BioCity Scotland was founded in 2012 and is owned 75% by BioCity Nottingham Ltd and 25% owned by Roslin Biocentre Ltd. It operates the former Merck Sharp & Dohme (MSD) research facilities at Newhouse. It acquired the Automated Compound Store (ACS) and recruited highly skilled scientists and technicians who built and managed the facility since it was first established by Organon Laboratories in 2006.  The site has been re-commissioned to provide the ACS facilities for the European Lead Factory. BCS is the centre of excellence for the compound management activities and is responsible for the collection, storage, distribution, HTS logistics and tracking of the EU Lead Factory Compound Collection.

The European Lead Factory is a novel platform for innovative drug discovery and is owned by a 30 partner consortium, the first of its kind. With the support of the IMI, it creates unprecedented opportunities for the discovery of new medicines by providing public partners with an industry like discovery platform to translate cutting edge academic research into high quality drug lead molecules on a scale and speed that was not possible previously.

Pharmaceutical companies have vast libraries of compounds which can be screened in the hunt for potential medicines. But usually, access to these compound libraries is highly restricted.  As part of the European Lead Factory, the 7 participating pharmaceutical companies will contribute at least 300,000 chemical compounds from their corporate chemical collections. A library of an estimated additional 200,000 novel compounds will be developed jointly by academia and SMEs. Together the two libraries will form a Joint European Collection consisting of up to half a million compounds that will be accessible to all project partners and to public organisations offering promising new targets for drug discovery screening. 

With Mosaic’s proven performance and efficiency, BioCity has chosen Titians Mosaic software to ensure the high performance of its compound management operations for the ELF. 

Dr Sylviane Boucharens, director of Discovery Operations says: ”We are excited to have been selected to provide Compound Management for the ELF consortium as part of the new IMI project. This is a great opportunity to get the most out our facility  the former Organon/Schering-Plough/MSD research site) at  Newhouse and its highly-skilled team of scientists who are the former MSD staff who have demonstrated vision and drive in reviving the automated compound store.

We selected Titian’s Mosaic Compound Management software as part of this process and have found it to be an effective and efficient solution. We look forward to working with Titian moving forward, and have no doubt that will enhance our ability to deliver positive outcomes throughout the course of this project.“

Titian CEO Edmund Wilson said: “We are delighted to see the revival of the extensive automated storage facility at Newhouse. That BioCity Scotland has chosen to re-implement Mosaic as its sample management system, reflects its success and reputation in the management of extensive and highly valuable compound libraries, and we are excited that Mosaic will play such an important role in this new chapter of European drug discovery.”

The go-to solution for automated sample management within the pharmaceutical and biotech industries, Titian’s Mosaic software suite provides optimised storage, tracking and ordering of a range of samples including small molecule compounds.  The highly flexible and modular software can be easily tailored for site specific workflows.  Integration with third party IT systems, existing infrastructure and an extensive range of automated instrumentation is also enabled, streamlining the workflow.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,400+ scientific posters on ePosters
  • More than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Titian Software launches Mosaic 4.0
Proven sample management software now encompasses biological samples and reagents
Friday, April 23, 2010
Scientific News
Adoption of Three Dimensional Culture Models May Save Lives
Physiologically relevant cell models can detect chronic hepatotoxicity early in the drug discovery process.
'Missing Evolutionary Link' of a Widely Used Natural Drug Source Found
A well-known family of natural compounds, called “terpenoids,” have a curious evolutionary origin. In particular, one question relevant to future drug discovery has puzzled scientists: exactly how does Nature make these molecules?
New Possibilities Tumor Research
Grazer researchers say gene activity of the tumor from the analysis of circulating DNA in blood ahead.
Game Changing Antibacterial Drug Research
Researchers publish report on the synthesis of a newly discovered “game-changing” antibiotic, Teixobactin.
New Hope for Zika Treatment Found in Large-Scale Screen of Existing Drugs
Johns Hopkins researchers join collaborative group to screen 6,000 existing drugs in hopes of finding treatments for Zika Virus infection
Mechanisms of Calcium Blockers
Researchers describe how the fundamental mode of action of two distinct chemical classes of calcium channel blockers differs.
Breakthrough in GPCR Understanding
Integral Molecular announces breakthrough in understanding the functionality of GPCRs, the largest class of drug targets in human disease.
Enzyme that Triggers Cell Demise in ALS Identified
Scientists from Harvard have identified a key instigator of nerve cell damage in people with amyotrophic lateral sclerosis (ALS).
Fly Study into Therapies for HVP-Induced Cancer
Fruit flies may help scientists understand the mechanism by which HPV can cause cancer as well as identify potential drug treatments.
World's Most In-Depth Study to Detect Alzheimer's Disease
A multisite team will see the most thorough and vigorous testing for Alzheimer's ever performed on volunteers.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!